drugset

drugset / Trial / NCT00209950

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

NCT00209950 ↗

Phase 3 Completed 200 enrolled H. Lundbeck A/S

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia

Timeline

Start: 2004-07
Primary completion: —
Completion: 2005-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	gaboxadol	Small molecule	—	—

Indications